Exploratory development

C. B. Willingham and R. T. Newbeig, Exploratory development of Fusion Cost Calcium Fluoridefor 1.06 Micrometer PulsedLaserOptics Piogiess Repoit, Sept. 25 to Dec. 25, 1976, NTIS Document COO-4029-2, Raytheon Co., foi U.S. Eneigy Research and Development Administiation, Jan. 1977. 

Conduct exploratory development for packaging of munitions which are assigned to ARMCOM... 

Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today 1998, 1, 387-393. 

The development of synthetic routes to new polyphosphazene structures began in the mid 1960 s (2-4). The initial exploratory development of this field has now been followed by a rapid expansion of synthesis research, characterization, and applications-oriented work. The information shown in Figure 3 illustrates the sequence of development of synthetic pathways to polyphosphazenes. It seems clear that this field has grown into a major area of polymer chemistry and that polyphosphazenes, as well as other inorganic macromolecules, will be used increasingly in practical applications where their unique properties allow the solution of difficult engineering and biomedical problems. 

Physicochemical profiling at the early discovery stage is important in the pharmaceutical industry because poor bioavailability is a leading factor in compound attrition. The ability to rapidly measure absorption properties such as solubility, log P, and log D allows promising compounds to quickly pass into exploratory development. 

M M. Rauhut, D. R. Maulding, W. Bergmark, B. G. Roberts, R. A. Clarke, and R. Coleman, Exploratory Development of Chemiluminescent Materials which Emit Radiation in the Infrared Region Final Technical Report to U.S. Army Munitions Command Contract DAAA 21-67-C-0503, Picatinny Arsenal, Dover, New Jersey 07801 October 1968. AD 843278 Unclassified Distribution limited to DOD and contractors. 

The term exploratory development (ED) can be defined as the first part of clinical drug development in which tolerabihty, pharmacokinetics and pharmacod)mamic activity are defined in man and in which an early indication of therapeutic efficacy is often obtained. A new molecular entity (NME) can be defined as an unlicensed new chemical or biological entity with activity in biological systems whose therapeutic potential is under investigation. The overall aim of ED should be to select appropriate NMEs for full development (ED), that is, commitment to licence application and to reject those that will not make useful medicines, as early as possible. 

Kays, A.O., Exploratory Development on Processing Science of Thick-Section Composites, Air Force Contract No. F33615-82-C-5059, Final Report for September 1982 to May 1985, AFWAL-TR-85-4090... 

Hadad, D. K.., Fritzen, J. S., May, C. A. Exploratory Developments of Chemical Quality Assurance and Composition of Epoxy Formulations, Air Force Materials Laboratory Technical Report, AFML-TR-77-217, (1978)... 

---